Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a biotechnology leader focused on developing gene therapies for rare neuromuscular and cardiac disorders, including Duchenne muscular dystrophy. This news hub provides investors and researchers with timely updates on the company's progress in advancing precision genetic medicines.
Access comprehensive coverage of SLDB's press releases, clinical trial milestones, financial disclosures, and strategic partnerships. Our curated news collection simplifies tracking critical developments in gene therapy innovation and regulatory advancements.
Key updates include announcements related to therapeutic pipelines, scientific collaborations, and market-moving events. Bookmark this page for streamlined access to verified information directly impacting SLDB's research trajectory and industry position.
Solid Biosciences Inc. (Nasdaq: SLDB) announced participation in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, scheduled for April 24, 2023, at 2:00 PM ET. The event will feature insights into the company's focus on developing genetic medicines for neuromuscular and cardiac diseases.
A live webcast will be accessible on the Company’s website, with a replay available afterward. Institutional investors interested in meetings during the conference can contact their Chardan representative. Solid Biosciences is known for programs like SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy, emphasizing a patient-centric approach to treatment.
Solid Biosciences Inc. (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023, at 8:00 AM ET. Additionally, he will join a gene therapy panel discussion later that same day at 11:45 AM ET. A live webcast of the presentation will be available on the company’s Investors section of their website, with a replay accessible post-event. The panel discussion will be exclusively available live to clients of Needham. Solid Biosciences is dedicated to developing genetic medicines targeting neuromuscular and cardiac diseases, with a focus on improving the daily lives of patients affected by these conditions.
Solid Biosciences (Nasdaq: SLDB) successfully completed the acquisition of AavantiBio, enhancing its focus on genetic medicines for cardiac and neuromuscular diseases. The company closed a $75 million private placement, positioning itself with approximately $214 million in cash, providing a runway into 2025. Solid is on track to submit an IND for SGT-003, a gene therapy for Duchenne muscular dystrophy, expected to commence dosing in late 2023. However, collaboration revenues decreased from $13.6 million in 2021 to $8.1 million in 2022, and the company's net loss widened to $86 million compared to $72.2 million in the previous year due to increased R&D investments.
Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will participate in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” during the BMO Biopharma Spotlight Series on March 28, 2023, at 9:00 AM ET. The live event is exclusive to BMO clients, with a replay available later on the Company’s website. Solid Biosciences is focused on developing genetic medicines for neuromuscular and cardiac diseases, with key programs including SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy. The Company aims to improve patients' lives through scientific and technological advancement.
FAQ
What is the current stock price of Solid Bioscience (SLDB)?
What is the market cap of Solid Bioscience (SLDB)?
